Analysis of the infectional profile of diabetic patients infected by COVID 19 in the period of 2020 – 2021 Análise do perfil de infecção dos pacientes diabéticos infectados pela COVID 19 no período de 2020-2021

Letícia Carla de Lima Cavalcante, Larissa Cristina de Lima Cavalcante, Maria Vitória Menezes Coutinho, Rebeca Montenegro de Lacerda, Rodrigo de Oliveira Arakaki, Cristiane Monteiro da Cruz


The COVID-19 disease has as its etiological agent the SARS-CoV-2, a RNA virus that causes severe respiratory syndrome. Diabetes mellitus is one of the significant risk factors for COVID-19 due to the weakened immune response of these patients and widely distribution of ACE2 in diferent organs. ACE2 is a receptor that antagonizes the RAS system, and is  related to the clinical symptoms of COVID 19 .Its expression in the islet cells and exocrine pancreas suggest the susceptibility for SARS-CoV 2 infection in diabetic patients. This stydy analyses the infeccional profile of diabetic patients infeccted by COVID-19 in the city of Maceió. A research was performed in the year of 2020-2021 in english idiom in the database PubMed using the descriptors “ACE receptor” AND “Covid”, “Covid” AND “Diabetes” AND “ ACE receptor” .The criteria of inclusion and exclusion established was the relevance and approach based on the theme to be discussed.It was collected data about confirmed deaths by Covid 19 according to preexisting comorbidities in the city of Maceió – AL shown in the graphics , expressing an average mortality among patients infected by Covid and preexisting Diabetes Mellitus. This study shows a reduction in the percentage of mortality in diabetic patients infected by Covid-19 seen in view of the adoption of measures to restrict the spread of the virus, reducing the numbers of infecion, especially the risk group, in addition to the vaccination campaign which culminated in positive results to the reduction in the mortality in infected diabetics.


COVID -19, Infection, Diabetes Mellitus.

Full Text:



BORNSTEIN, S. R, et al. Endocrine and metabolic link to coronavirus infection. Nature Reviews Endocrinology, v. 16, p. 297-298, abr. 2020.

CHENG, H; Wang, Y; Wang, G. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. Journal of Medical Virology, v. 92, n. 7, p. 726-730, jul.2020.

DAS, S et al. Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. Elsevier Public Health Emergency Collection, v. 258, out. 2020.

DATTA, P.K et al. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. v.10, n.16, p.7448-7464, jun.2020.

GARG, M. K et al. Endocrine Involvement in COVID-19: Mechanisms, Clinical Features, and Implications for Care. Indian Journal of Endocrinology and Metabolism, v. 24, n.5, p.381-386, set – out. 2020.

GUPTA, R; HUSSAIN, A; MISRA, A. Diabetes and COVID-19: evidence, current status and unanswered research questions. European Journal of Clinical Nutrition, v. 74, n. 6, p.864-870, jun.2020.

HIPPISLEY-COX, J, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. BMJ Journal, v.106, p. 1503-1511, jul. 2020.

LI, Y et al. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Elsevier Public Health Emergency Collection, v. 157, jul.2020.

MACEDO, J. L, et al. Epidemiological profile of diabetes mellitus in northeastern Brazil. Research, Society and Development, [S. l.], v. 8, n. 3, p. e2883826, 2019.

PATHANGEY, G et al. Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies. American Journal of Physiology, v.320, n. 3, p. L301 – L330, mar.2021

TETLOW, S et al. ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19. Journal of Internal Medicine. v.289, n.5, p. 688-699, dez.2020.



  • There are currently no refbacks.